US 12,220,426 B2
Type 1 helper t cell-increasing agent, food and pharmaceutical
Hiroshi Ohno, Wako (JP); Tadashi Takeuchi, Wako (JP); Shu Shimamoto, Tokyo (JP); Shuuji Yoshioka, Tokyo (JP); Eiji Miyauchi, Wako (JP); and Hiroki Negishi, Wako (JP)
Assigned to DAICEL CORPORATION, Osaka (JP)
Appl. No. 17/284,927
Filed by DAICEL CORPORATION, Osaka (JP)
PCT Filed Oct. 24, 2019, PCT No. PCT/JP2019/041599
§ 371(c)(1), (2) Date Apr. 13, 2021,
PCT Pub. No. WO2020/085407, PCT Pub. Date Apr. 30, 2020.
Claims priority of application No. 2018-201181 (JP), filed on Oct. 25, 2018.
Prior Publication US 2021/0379097 A1, Dec. 9, 2021
Int. Cl. A61K 31/717 (2006.01); A23L 33/10 (2016.01); A61P 35/00 (2006.01)
CPC A61K 31/717 (2013.01) [A23L 33/10 (2016.08); A61P 35/00 (2018.01)] 11 Claims
 
1. A method of increasing type 1 helper T cells, which comprises administering a type 1 helper T cell-increasing agent comprising a cellulose derivative as an active ingredient, the cellulose derivative having a degree of butyryl substitution of 0.3 or greater and 2.6 or less, and a total degree of substitution of 0.5 or greater and 2.8 or less, wherein the increase in type 1 helper T cells treats and/or reduces the likelihood of a tumor.